Akers Biosciences Inc (LON:AKR)‘s stock had its “corporate” rating reissued by investment analysts at FinnCap in a research report issued to clients and investors on Tuesday.

Shares of Akers Biosciences (LON:AKR) remained flat at $GBX 56 ($0.74) on Tuesday. Akers Biosciences has a 12 month low of GBX 60 ($0.79) and a 12 month high of GBX 255 ($3.35).

COPYRIGHT VIOLATION WARNING: “Akers Biosciences Inc (AKR) Rating Reiterated by FinnCap” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/23/akers-biosciences-inc-akr-rating-reiterated-by-finncap.html.

Akers Biosciences Company Profile

Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.

Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.